Plus therapeutics to present multi-institutional experience using the cnside™ cerebrospinal fluid assay in patients with leptomeningeal metastases

Cnside cerebrospinal fluid (csf) assay analyzed 258 csf samples across 66 leptomeningeal metastases (lm) patients at five institutions cnside identified extensive, actionable mutational changes, and clinically relevant longitudinal biomarkers austin, texas, nov. 21, 2024 (globe newswire) -- cnside diagnostics, llc, a wholly owned subsidiary of plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), will present data demonstrating the utility of the cnside csf assay platform in identifying mutations of key biomarkers in the csf and their implications in treatment selection for lm. the data will be presented at the 2024 society for neurooncology (sno) annual meeting november 21-24 in houston, texas.
pstv Ratings Summary
pstv Quant Ranking